Mark For: DICHAMA™ trademark registration is intended to cover the categories of pharmaceutical preparations for the treatment of sarcoidosis, interstitial lung disease, pulmonary fibrosis, and idiopathic pulmonary fibrosis; Pharmaceutical preparations for the treatment of pulmonary hypertension, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with lung disease, pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease, portopulmonary hypertension, pulmonary hypertension associated with sleep-related breathing disorders, pulmonary hypertension associated with chronic thrombotic and embolic disease, and pulmonary hypertension secondary to hematologic, metabolic, renal, granulomatous, or fibrotic disorders.
Status
2023-02-11 UTC
LIVE APPLICATION Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Peter J. Willsey
Attorney Docket Number
35555/273
Timeline
2023-02-07
Application Filed
2023-02-10
Location: NEW APPLICATION PROCESSING
2023-02-10
Status: Live/Pending
2023-02-10
Status: New application awaiting assignment to an examining attorney. See current trademark processing wait times for more information.
PETER J. WILLSEY BROWN RUDNICK LLP 601 THIRTEENTH STREET NW SUITE 600 WASHINGTON, DC 20005
Good, Services, and Codes
International Codes:
5
U.S. Codes:
005,006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations for the treatment of sarcoidosis, interstitial lung disease, pulmonary fibrosis, and idiopathic pulmonary fibrosis; Pharmaceutical preparations for the treatment of pulmonary hypertension, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with lung disease, pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease, portopulmonary hypertension, pulmonary hypertension associated with sleep-related breathing disorders, pulmonary hypertension associated with chronic thrombotic and embolic disease, and pulmonary hypertension secondary to hematologic, metabolic, renal, granulomatous, or fibrotic disorders
Trademark Filing History
Description
Date
Proceeding Number
NEW APPLICATION ENTERED
2023-02-10
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.